Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.63% | -1.13% | -2.36% | -0.34% | 9.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.63% | -1.13% | -2.36% | -0.34% | 9.58% |
| Cost of Revenue | -2.85% | 7.28% | -6.13% | 6.32% | 11.54% |
| Gross Profit | -5.53% | -5.10% | -0.16% | -3.80% | 8.62% |
| SG&A Expenses | -4.75% | 2.27% | 1.02% | -2.10% | 3.08% |
| Depreciation & Amortization | -4.61% | 0.68% | -0.63% | 162.66% | -63.83% |
| Other Operating Expenses | 136.67% | -87.81% | 16.21% | 93.76% | -229.67% |
| Total Operating Expenses | 1.86% | -2.44% | 1.27% | 30.17% | -23.62% |
| Operating Income | -29.52% | 5.84% | -23.20% | -78.35% | 264.53% |
| Income Before Tax | -76.21% | 19.00% | -119.93% | -58.28% | 220.88% |
| Income Tax Expenses | 47.50% | -31.15% | 90.81% | 105.59% | 155.20% |
| Earnings from Continuing Operations | -112.84% | 40.74% | -3,254.14% | -78.19% | 286.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -18.96% | 23.81% | -131.29% | -27.20% | 1.18% |
| Net Income | -112.92% | 40.77% | -3,229.30% | -78.22% | 286.26% |
| EBIT | -29.52% | 5.84% | -23.20% | -78.35% | 264.53% |
| EBITDA | -17.86% | 3.90% | -16.69% | -50.23% | 987.43% |
| EPS Basic | -112.96% | 41.16% | -3,192.31% | -78.45% | 284.09% |
| Normalized Basic EPS | -33.80% | 2.92% | -29.64% | -89.18% | 199.20% |
| EPS Diluted | -113.18% | 40.82% | -3,192.31% | -78.45% | 281.08% |
| Normalized Diluted EPS | -32.68% | 2.69% | -29.64% | -89.18% | 197.55% |
| Average Basic Shares Outstanding | -0.34% | -0.27% | 0.84% | 1.04% | 1.17% |
| Average Diluted Shares Outstanding | -1.99% | -0.06% | 0.84% | 1.04% | 2.88% |
| Dividend Per Share | 2.85% | -- | 1.56% | -- | 1.32% |
| Payout Ratio | -8.45% | -0.19% | 0.97% | 3.68% | 1.53% |